Revenue segments as reported by the company.

Subscription services

Professional services and other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Sales and marketing

General and admin

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Veeva Systems

Veeva Systems, Inc. engages in the provision of industry cloud solutions for the global life sciences industry. Its solutions enable pharmaceutical and other life sciences companies to realize the benefits of modern cloud-based architectures and mobile applications for their most critical business functions, without compromising industry-specific functionality or regulatory compliance. The firm's customer relationship management solutions enable its customers to increase the productivity and compliance of their sales and marketing functions. Its regulated content management and collaboration solutions enable its customers to more efficiently manage regulated, content-centric processes across the enterprise. The company's customer master solution enables customers to more effectively manage complex healthcare provider and healthcare organization data. The company was founded by Mark Armenante, Peter P. Gassner, Doug Ostler, Mitch Wallace and Matthew J. Wallach on January 12, 2007, and is headquartered in Pleasanton, CA.

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Earnings data Q3 2025

Veeva Systems reports robust Q1 earnings, eyes growth opportunities

Veeva Systems delivered strong financial performance in Q1 2023, driven by robust execution and competitive wins. The company's focus on innovation, AI capabilities, and the transition to Vault CRM presents significant growth opportunities. However, challenges in the funding environment and customer migrations pose potential hurdles.

Veeva exceeds Q2 expectations, anticipates growth in clinical and data business

Veeva's Q2 performance exceeded expectations, leading to an increase in full-year guidance. The company's strengths lie in strong clinical activity, customer wins, and a focus on product excellence. However, challenges include migration costs, competitive landscape considerations, and marketing spend scrutiny. Veeva sees opportunities in M&A, minimal impact from R&D trends, and expansion of Veeva Link.

Veeva Systems surpasses Q3 expectations, eyes clinical data opportunity

Veeva Systems delivered a strong Q3 performance, with solid revenue and operating income. While facing challenges in billings and macroeconomic uncertainties, the company remains confident in its revenue target for fiscal year '25. The commitment from major enterprises and the potential in clinical data present significant opportunities for future growth.

Veeva Systems reports strong Q4 performance and forecasts $2.8B revenue

Veeva Systems showcases strong performance and strategic planning with revenue growth expectations of at least 15% in fiscal '24 and '25.
Positive feedback on product transitions and development, along with specialized sales teams, highlights market acceptance and innovation.
Challenges include short-term revenue impacts from timing-related issues and macro environment effects on customer spending.
Opportunities lie in revenue growth forecasts, product innovation, and market differentiation through new offerings and strategic deals.

Veeva Systems reports robust Q1 revenue growth and strategic focus

Veeva Systems' Q1 performance reflects strong revenue growth and a focus on customer-centric innovation. The company faces challenges in project scrutiny and competition but has opportunities in new product monetization and segment expansion.

Veeva Systems excels in Q2, eyes disciplined growth and innovation

Veeva Systems showcased robust financial performance, exceeding revenue and operating income targets, with a strong focus on customer success and product excellence.
While facing challenges such as migration costs and regulatory impacts, Veeva is well-positioned to leverage opportunities in disciplined M&A and product innovation.
The company's strategic growth initiatives, including Veeva Link expansion and CRM platform enhancements, aim to drive continued success and value for customers.

Veeva Systems posts solid Q3 results, eyes growth opportunities

Veeva Systems delivered a strong Q3 performance with solid revenue and operating income, showcasing financial stability and growth potential.
Despite challenges like trimmed billings and deal delays, Veeva remains confident in its fiscal year '25 revenue target, emphasizing strategic focus and operational efficiency.
The company's strengths in innovative products, strong partnerships, and global support ecosystem position it well for future growth and market leadership.
Opportunities in customer migration, AI integration, and market demand present avenues for Veeva to drive revenue growth and enhance its competitive positioning in the industry.

Veeva Systems excels in Q4 earnings, poised for strategic growth

Veeva Systems delivered strong financial performance in Q4 2024, showcasing revenue growth, operating income efficiency, and strategic product advancements.
The company's focus on innovation, customer success, and disciplined financial guidance positions it well for future growth and market leadership.
While facing challenges related to market uncertainties and operational considerations, Veeva remains resilient and poised to capitalize on opportunities for expansion and differentiation.
Overall, Veeva's Q4 earnings call highlights a balanced approach to growth, operational excellence, and strategic decision-making in a dynamic business environment.

Veeva Systems beats Q1 guidance, lowers full-year outlook amid challenges

Veeva Systems had a strong start to the year, exceeding Q1 guidance but lowering full-year revenue outlook due to macro challenges.
The company's performance in margin, client adoption, and innovation remains robust, with a focus on stability and predictability amidst industry challenges.
Challenges include AI disruption impacting plans, lower revenue guidance, and delays in funding benefits due to global conflicts and interest rate sensitivity.
Opportunities lie in new client bases, EDC deals progress, and the potential growth of Vault Basics and Link products in the market.

Veeva Systems excels in Q2, eyes strategic growth opportunities

Veeva Systems delivered a strong Q2 performance with revenue of $676 million and non-GAAP operating income of $280 million, driven by product expansions and customer wins.
The company's strengths lie in its comprehensive clinical suite, customer comfort with CRM solutions, and the importance of professional services for customer success.
Challenges include short-term billing growth constraints and the need for continuous product excellence, while opportunities exist in data architecture enhancement and upcoming Investor Day insights.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Align Technology

Intuitive Surgical

Here are some terrific options for investors who just want to set it and forget it.

3 Unstoppable Healthcare Stocks to Buy Now and Hold Forever

PLEASANTON, Calif., Aug. 4, 2021 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) will announce financial results for its second fiscal quarter, which ended July 31, 2021, after market close on September 1, 2021.

Veeva to Release Fiscal 2022 Second Quarter Results on September 1, 2021

PLEASANTON, Calif. and CORK, Ireland, Aug. 3, 2021 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced that it has acquired Learnaboutgmp, a leading provider of accredited GxP training for life sciences.

Veeva Acquires Learnaboutgmp, a Leading GxP eLearning Content Provider

Veeva Systems (VEEV) closed at $332.78 in the latest trading session, marking a +0.02% move from the prior day.

Veeva Systems (VEEV) Gains As Market Dips: What You Should Know

Microsoft

Teladoc

Teaming up is smart for Microsoft and Teladoc.

Could the Microsoft-Teladoc Partnership Threaten Veeva Systems?

Salesforce

PayPal

Salesforce, Veeva, and PayPal all have rosy expectations for the future.

These 3 Tech Companies Could Double Their Revenues by 2025

AKRON, Ohio--(BUSINESS WIRE)--Drips, the founders of Conversational Texting®, today announced the appointment of Greg Williams to its board of directors. Drips' AI-powered platform enables brands to engage with their audiences through Conversational Texting® and scheduled calling. Williams will advise on strategy, expansion and product innovation as Drips harnesses its rapid growth as the industry leader in AI-powered SMS messaging. This appointment follows a significant investment from Accel-K

Drips Names Greg Williams to Board of Directors

CrowdStrike

Recurring revenue and network effects make these terrific stocks to buy on the dips.

3 Stocks to Buy in the Upcoming Market Crash

HealthEquity

Allscripts Healthcare Solutions

Tabula Rasa Healthcare

Health IT stocks like HealthEquity (HQY), Veeva Systems (VEEV), Tabula Rasa (TRHC) and Allscripts (MDRX) are expected to continue their run over the next few months.

MedTech Thrives on Healthcare IT in 2021: 4 Stocks to Focus on

Veeva Systems is one of the most successful startups in the enterprise SaaS industry. What does Veeva Systems do?

Veeva Systems: What Investors Can Learn From This Wildly Successful Enterprise

Netflix

Starbucks

Choosing between these stocks and the digital currency is an extremely easy decision.

3 Overpriced Stocks That Are Still Better Investments Than Dogecoin

DocuSign

Tech options trades have roared back to life… the power of trading LEAPS on elite companies… blending options with fundamentally-superior stocks   When's the last time you had a position go from a double-digit loss to a 50%+ gain? If you're invested in stocks, this type of reversal of fortune isn't a regular occurrence.

From Down Big to Up Big

Veeva (VEEV) is well positioned to outperform the market, as it exhibits above-average growth in financials.

Here is Why Growth Investors Should Buy Veeva (VEEV) Now

Veeva Systems (VEEV) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.

Moving Average Crossover Alert: Veeva Systems (VEEV)

Schrodinger 

I'm an owner of Schrodinger because this company's software is revolutionizing drug discovery, and it's going to be a monster stock over the next decade.

My Favorite Biotech Stock Right Now

Dropbox

Everbridge

PagerDuty

Atlassian

Thor Industries

Twilio

Twitter

Workday

Slack

Zoom Video

The Fed's meeting was the (expected) smallest of tone shifts, rather than a major policy adjustment. One of the sectors that emerged as a winner in the market's eyes? SaaS (software as a service) stocks. New boss, same as the old boss.

SaaS Stocks: A Post-Fed Winner, But Mind The Hangover (Podcast)

Becton, Dickinson and Co.

Henry Schein

Here we look at three stocks, VEEV, HSIC and BDX, that investors can keep a watch on the back of their robust cybersecurity measures.

Cybersecurity Gains Prominence in Healthcare: 3 Stocks to Watch

As of late, it has definitely been a great time to be an investor in Veeva Systems Inc. (VEEV).

Veeva Systems' (VEEV) Shares March Higher, Can It Continue?

Veeva (VEEV) could produce exceptional returns because of its solid growth attributes.

Looking for a Growth Stock? 3 Reasons Why Veeva (VEEV) is a Solid Choice

Veeva Link's expansion across 11 new therapeutic areas to drive engagement for Veeva's (VEEV) partner companies with key experts.

Veeva (VEEV) Customer Intelligence Platform Reaches New Areas

Tandem Diabetes Care

These two companies are less volatile than the cryptocurrency, and they offer better long-term prospects, too.

2 Unstoppable Growth Stocks That Can Make You Richer Than Dogecoin

Here's a healthcare stock you may not have heard of, but it's definitely worth watching.

1 Life Science Stock to Watch in 2021 and Beyond

AbbVie

Buying these stocks on the dips could lead to oversized returns with very little risk.

2 Top Healthcare Stocks to Buy in a Market Crash

Veeva is a consistent compounder that is putting out roughly 25% CAGR.

Veeva: Stable And Steady Compounding Machine

PLEASANTON, Calif., June 9, 2021 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced the availability of 11 new therapeutic areas in the Veeva Link customer intelligence platform.

News for Veeva Systems Stock (VEEV)